ORIC Pharmaceuticals to Present Phase 1b Enozertinib Data in First-Line Lung Cancer at ESMO 2026

Bitget2026/10/19 12:11

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

ORIC Pharmaceuticals will review ongoing Phase 1b enozertinib trial data during an October 23, 2026, webcast at 8 a.m. ET.
The study targets previously untreated metastatic lung cancer with atypical EGFR mutations; findings will be presented October 26 at ESMO Congress.
Other planned presentations include a Phase 3 rinzimetostat combination study in previously treated metastatic prostate cancer.
A separate rinzimetostat poster reports restricted cellular plasticity in preclinical models and mechanistic proof of concept in prostate cancer patient samples.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oric Pharmaceuticals Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190800PRIMZONEFULLFEED9847738) on October 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

ORIC Pharmaceuticals to Present Phase 1b Enozertinib Data in First-Line Lung Cancer at ESMO 2026

You may also like

Crypto prices